Outcomes	O

The	O
primary	O
outcome	O
was	O
the	O
reduction	B-PrimaryOutcome
of	I-PrimaryOutcome
viral	I-PrimaryOutcome
RNA	I-PrimaryOutcome
load	I-PrimaryOutcome
in	O
nasopharyngeal	O
swabs	O
at	B-TimeFrame
days	I-TimeFrame
3	I-TimeFrame
and	I-TimeFrame
7	I-TimeFrame
after	I-TimeFrame
treatment	I-TimeFrame
start	I-TimeFrame
.	O

The	O
secondary	O
outcomes	O
were	O
clinical	B-SecondaryOutcome
progression	I-SecondaryOutcome
measured	O
using	O
a	O
simplified	O
version	O
of	O
the	O
WHO	B-OutcomeDefinition
progression	I-OutcomeDefinition
scale	I-OutcomeDefinition
[	O
17	O
]	O
(	O
1	O
,	O
not	O
hospitalized	O
with	O
or	O
without	O
resumption	O
of	O
normal	O
activities	O
;	O
2	O
,	O
hospitalized	O
,	O
requiring	O
supplemental	O
oxygen	O
;	O
3	O
,	O
hospitalized	O
,	O
requiring	O
invasive	O
mechanical	O
ventilation	O
;	O
and	O
4	O
,	O
death	O
)	O
and	O
time	B-SecondaryOutcome
from	I-SecondaryOutcome
randomization	I-SecondaryOutcome
to	I-SecondaryOutcome
complete	I-SecondaryOutcome
resolution	I-SecondaryOutcome
of	I-SecondaryOutcome
symptoms	I-SecondaryOutcome
within	B-TimeFrame
the	I-TimeFrame
28	I-TimeFrame
-	I-TimeFrame
day	I-TimeFrame
follow	I-TimeFrame
-	I-TimeFrame
up	I-TimeFrame
period	I-TimeFrame
.	O

Resolution	B-OutcomeDefinition
of	I-OutcomeDefinition
symptoms	I-OutcomeDefinition
was	I-OutcomeDefinition
assessed	I-OutcomeDefinition
sequentially	I-OutcomeDefinition
using	I-OutcomeDefinition
a	I-OutcomeDefinition
symptoms	I-OutcomeDefinition
questionnaire	I-OutcomeDefinition
designed	I-OutcomeDefinition
to	I-OutcomeDefinition
gather	I-OutcomeDefinition
information	I-OutcomeDefinition
on	I-OutcomeDefinition
the	I-OutcomeDefinition
type	I-OutcomeDefinition
of	I-OutcomeDefinition
symptom	I-OutcomeDefinition
and	I-OutcomeDefinition
last	I-OutcomeDefinition
day	I-OutcomeDefinition
experienced	I-OutcomeDefinition
;	O
complete	O
resolution	O
was	O
considered	O
when	O
no	O
COVID	O
-	O
19	O
â€“	O
related	O
symptoms	O
were	O
reported	O
at	O
all	O
.	O

Safety	O
outcomes	O
included	O
AEs	B-OtherOutcome
that	I-OtherOutcome
occurred	I-OtherOutcome
during	I-OtherOutcome
treatment	I-OtherOutcome
,	O
SAEs	B-OtherOutcome
,	O
AEs	B-OtherOutcome
of	I-OtherOutcome
special	I-OtherOutcome
interest	I-OtherOutcome
(	I-OtherOutcome
ie	I-OtherOutcome
,	I-OtherOutcome
cardiac	I-OtherOutcome
)	I-OtherOutcome
,	O
and	O
premature	B-OtherOutcome
discontinuation	I-OtherOutcome
of	I-OtherOutcome
therapy	I-OtherOutcome
.	O

AEs	O
were	O
classified	B-OutcomeDefinition
according	I-OutcomeDefinition
to	I-OutcomeDefinition
the	I-OutcomeDefinition
National	I-OutcomeDefinition
Cancer	I-OutcomeDefinition
Institute	I-OutcomeDefinition
Common	I-OutcomeDefinition
Terminology	I-OutcomeDefinition
Criteria	I-OutcomeDefinition
for	I-OutcomeDefinition
Adverse	I-OutcomeDefinition
Events	I-OutcomeDefinition
,	O
version	O
4	O
.	O
0	O
.	O

All	O
unexpected	O
SAEs	O
were	O
notified	O
through	O
Eudravigilance	O
.	O

